As TAVI expands to younger and healthier patients, valve durability has become an increasingly important consideration. However, the optimal antithrombotic strategy to support long-term valve function remains unclear. This trial compared antiplatelet monotherapy with NOAC monotherapy to help address this unmet need. 

In this episode, Deepak L. Bhatt MD, MPH, MBA, FACC and Øyvind H. Lie, MD, PhD, MSc examine the results of "ACASA-TAVI: Antithrombotic therapy after TAVI". 

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör American College of Cardiology. Innehållet i podden är skapat av American College of Cardiology och inte av, eller tillsammans med, Poddtoppen.